Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYNOTE-585 perioperative pembrolizumab plus chemotherapy in gastric/GEJ adenocarcinoma
2016-004408-76Phase 3Active
- Sponsor
- Merck & Co.
- Start
- Jun 2017
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma comparing Pembrolizumab plus chemotherapy with Placebo plus chemotherapy (2 arms). Started Jun 2017; status: active.
02
Drugs
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on 2016-004408-76.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-004408-76.